Growth hormone therapy in short stature children

Kee Hyong Lee

    Research output: Contribution to journalArticlepeer-review

    3 Citations (Scopus)

    Abstract

    Since 1985 recombinant DNA-derived human growth hormone (hGH) became available for treatment of various growth disorders in children. GH stimulates linear growth in children with growth hormone deficiency (GHD) and also demonstrates efficacy In the treatment of Turner syndrome, chronic renal failure, Prader-Willi syndrome, and growth failure secondary to small for gestational age (SGA). Although recently FDA approved GH therapy for idiopathic short stature, the effect of GH treatment remains unclear. GH therapy is generally safe but GH has potential side effects. The decision of GH therapy in idiopathic short stature should be made individualized under consideration of the efficacy, cost-effectiveness, and psychosocial aspects, and GH therapy must be carried out by pediatric endocrinologists or experienced physicians.

    Original languageEnglish
    Pages (from-to)849-855
    Number of pages7
    JournalJournal of the Korean Medical Association
    Volume51
    Issue number9
    DOIs
    Publication statusPublished - 2008 Sep

    Keywords

    • Child
    • Efficacy
    • Growth hormone
    • Safety
    • Short stature

    ASJC Scopus subject areas

    • Medicine(all)

    Fingerprint

    Dive into the research topics of 'Growth hormone therapy in short stature children'. Together they form a unique fingerprint.

    Cite this